PerkinElmer Inc. Stock
PerkinElmer Inc. Stock
The price for the PerkinElmer Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.350 (-0.290%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the PerkinElmer Inc. stock is not clear.
On the other hand, the target price of €110.00 is below the current price of €121.40 for PerkinElmer Inc., so the potential is actually -9.390%.
So far the community has only identified positive things for PerkinElmer Inc. stock. The most positive votes were given for criterium "Growth compared to competition".
Pros and Cons of PerkinElmer Inc. in the next few years
Pros
1
Growths faster than the competition
1
Could be worthwhile Investment >10% per year
1
EBIT growth >5% per year expected
Cons
0
-
Performance of PerkinElmer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| PerkinElmer Inc. | -0.290% | 6.171% | 4.031% | 40.231% | 5.478% | 78.988% | 154.037% |
| Thermo Fisher Scientific Inc. | 0.830% | 4.120% | 1.721% | 27.206% | 0.920% | 105.379% | 185.428% |
| Illumina Inc. | -0.610% | 8.874% | 21.770% | 23.336% | 24.817% | 52.884% | 202.555% |
| Edwards Lifesciences Corp. | 0.820% | 4.797% | 13.559% | 36.790% | 12.461% | 476.141% | - |
Comments
Other discussions about PerkinElmer Inc. Stock
Trading PerkinElmer Inc.
Trading PerkinElmer Inc.
News
PerkinElmer to Host Virtual Investor and Analyst Day
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24
PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX®
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec
